Eli Lilly and Company Common St (NYSE:LLY):
Elanco Releases First-Ever Corporate Social Responsibility Impact Report.
The company is down by -0.31% since yesterday’s close of $81.04.
Additionally Eli Lilly and Company Common St recently declared a dividend for shareholders paid on Friday the 9th of June 2017. The dividend payment was $0.520 per share for the quarter or $2.08 on an annualized basis. This dividend represents a yield of $2.57. The ex-dividend date was set for Thursday the 11th of May 2017.
Eli Lilly and Company, launched on January 17, 1901, is involved in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Business’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Business’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries..
It is currently trading at $80.79 which is just over $80.11, the 50 day moving average and slightly over the 200 day moving average of $78.56. The 50 day moving average went up $0.62 or +0.77% and the 200 day average moved up $2.17.
The P/E ratio is 39.04 and market capitalization is 85.28B. In the last earnings report the EPS was $2.07 and is estimated to be $4.12 for the current year with 1,056,300,000 shares currently outstanding. Analysts expect next quarter’s EPS will be $1.05 with next year’s EPS anticipated to be $4.37.
Brokerages have released ratings on the company recently. On November 25 the stock rating was downgraded to “Market Perform” from “Outperform” with a current price target of $64.00 in a report issued by BMO Capital. BMO Capital both downgraded the stock and lowered the price target on November 25 changing the price target from $100.00 to $64.00 and cutting the rating from “Outperform” to “Market Perform”.
On November 25, 2016 the stock rating was rated “Neutral” according to a Atlantic Equities report which is down from the previous “Overweight” rating. On September 8 the company was changed to a “Overweight” in a report from JP Morgan up from the previous “Neutral” rating.
May 2 investment analysts at Leerink Swann kept the stock rating at “Outperform” and raised the price target to $91.00 from $90.00. On May 1 Credit Suisse maintained a company rating of “Outperform” but lowered the price target from $105.00 to $91.00.